Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 20;41(15):2706-2712.
doi: 10.1200/JCO.23.00225. Epub 2023 Mar 17.

Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival

Margret Merino  1 , Yvette Kasamon  1 , Marc Theoret  1   2 , Richard Pazdur  1   2 , Paul Kluetz  1   2 , Nicole Gormley  1
Affiliations

Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival

Margret Merino et al. J Clin Oncol. .

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Margret Merino

Employment: Spectrum Primary Care Incorporated, Chenega Professional Services

No other potential conflicts of interest were reported.

References

    1. Richardson NC, Kasamon Y, Pazdur R, et al. : The saga of PI3K inhibitors in haematological malignancies: Survival is the ultimate safety endpoint. Lancet Oncol 23:563-566, 2022 - PubMed
    1. US Food and Drug Administration : FDA briefing document for the Oncologic Drugs Advisory Committee (ODAC) Meeting, April 21, 2022. Phosphatidylinositol 3-kinase (PI3K) inhibitors in hematologic malignancies. https://www.fda.gov/media/157762/download
    1. Kumar SK, Harrison SJ, Cavo M, et al. : Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 21:1630-1642, 2020 - PubMed
    1. Schjesvold FH, Dimopoulos MA, Delimpasi S, et al. : Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): A randomised, head-to-head, open-label, phase 3 study. Lancet Haematol 9:e98-e110, 2022 - PubMed
    1. GlaxoSmithKline : Dear Health Care Provider Letter, May 2022. Important drug warning: Zejula (niraparib) important drug warning for the maintenance treatment in recurrent ovarian cancer (2L+). https://www.zejulahcp.com/content/dam/cf-pharma/hcp-zejulahcp-v2/​en_US/...